Nahor Haddish-Berhane - Pfizer Inc | 人才画像

基本信息

浏览量：1

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 45 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Bioequivalence of 240 Mg Apalutamide Tablets and Preparation in Aqueous Food Vehicles for Alternative Administration

Alex Yu, Mieke Van Uffel, Juhui J. Jiao, Rosamerlinda Rosales, Maura Erba,Nahor Haddish-Berhane

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENTno. 4 (2024): 432-439

引用0浏览0WOS引用

Subcutaneous Versus Intravenous Amivantamab, Both in Combination with Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results from the Phase III PALOMA-3 Study

JOURNAL OF CLINICAL ONCOLOGYno. 30 (2024)

引用0浏览0WOS引用

Effect of Erdafitinib on the Pharmacokinetics of Midazolam and Metformin in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations

Wei Zhu,Mahadi Baig,Vahid Naini,Marc De Meulder,Sydney Akapame,Loeckie De Zwart,Nahor Haddish-Berhane,Spyros Triantos

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT（2024）

引用0浏览0WOS引用

Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation

Alex Yu,Anasuya Hazra,James Juhui Jiao,Peter Hellemans,Anna Mitselos, Hui Tian,Juan Jose Perez Ruixo,Nahor Haddish-Berhane,Daniele Ouellet,Alberto Russu

CLINICAL PHARMACOKINETICSno. 4 (2024): 511-527

引用0浏览0WOS引用

Dose Optimization in Oncology Drug Development: an International Consortium for Innovation and Quality in Pharmaceutical Development White Paper

Divya Samineni,Karthik Venkatakrishnan,Ahmed A. Othman,Yazdi K. Pithavala,Srinivasu Poondru,Chirag Patel,Pavan Vaddady, Wendy Ankrom,Saroja Ramanujan,Nageshwar Budha,Michael Wu,Nahor Haddish-Berhane,Holger Fritsch,Azher Hussain,Jitendra Kanodia, Meng Li,Mengyao Li,Murad Melhem,Apurvasena Parikh,Vijay V. Upreti,Neeraj Gupta

Clinical Pharmacology &amp Therapeutics (2024)

引用0浏览0WOS引用

Less Frequent Teclistamab Dosing in Responders: Modeling and Simulation Data from the Majestec-1 Study in Relapsed/Refractory Multiple Myeloma

Yue Guo, Jin Niu, Natalia A Quijano Cardé,Liviawati Wu, Xin Miao, Shalla Hanson,Yaming Su, Carlos Pérez Ruixo,Deeksha Vishwamitra,Katherine Chastain,Mahesh Samtani, Weirong Wang,Nahor Haddish-Berhane

Bloodno. Supplement 1 (2024): 1989-1989

引用0浏览0引用

Subcutaneous Versus Intravenous Amivantamab, Both in Combination with Lazertinib, in Refractory EGFR-mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study

Journal of Clinical Oncology (2024)

引用0浏览0引用

Model-Based Exploration of the Impact of Prophylactic Tocilizumab on IL-6 Dynamics in Multiple Myeloma Patients Receiving Teclistamab Treatment

Jia Zhou,Deeksha Vishwamitra,Yue Guo,Raluca Verona,Alfredo Perales Puchalt,Tara Stephenson,Caroline Hodin,Arnob Banerjee,Katherine Chastain,Nahor Haddish-Berhane,Weirong Wang

BLOOD（2023）

引用1浏览0引用

Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non-Small Cell Lung Cancer

Nahor Haddish-Berhane,Yaming Su,Alberto Russu,Meena Thayu,Roland E. Knoblauch,Jaydeep Mehta,John Xie, Eric Gibbs,Yu-Nien Sun,Honghui Zhou

Clinical Pharmacology & Therapeuticsno. 3 (2023): 468-477

引用3浏览0WOS引用

Effects of Food and Race on the Pharmacokinetics of Lazertinib in Healthy Subjects and Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer

Ki Young Huh,Yeji Lim,Deok Yong Yoon,Jun Gi Hwang,Sujin Sim, Jiah Kang,Jangyoung Wang, Mikyung Kim,Seong Bok Jang,S. Martin Shreeve,Jaydeep Mehta,Nahor Haddish-Berhane,Jaeseong Oh,Seunghwan Lee,Kyung-Sang Yu

LUNG CANCER（2023）

引用1浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn